Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Iconic Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.iconictherapeuti...
Year Founded: 2002
Status: Private
BioCentury | Oct 5, 2021
Management Tracks
Bernstein becomes CMO at BioMarin
Plus: Novavax, TPG, Noema, Syndax, Prothena, Annexon, ProQR and more
BioCentury | Apr 29, 2021
Management Tracks
Cytovia names Frankel CMO; plus Bantam, GreenLight, Edgewise, CohBar and more
CAR NK cell therapy and antibody play Cytovia Therapeutics Inc. hired Stanley Frankel as CMO. Frankel was SVP of cellular therapy development at Bristol Myers Squibb Co. (NYSE:BMY). Bantam
BioCentury | Dec 3, 2020
Finance
Dec. 2 Quick Takes: venture rounds for Genesis, Biosight; plus: Frontier-AbbVie, Exelixis-Iconic, UCB-Specifica and Click
AI company Genesis raises $52M series AStanford University spinout Genesis Therapeutics Inc. raised $52 million in a series A round led by Rock Springs Capital; T. Rowe Price Associates, Andreessen
BioCentury | Mar 6, 2020
Management Tracks
Sharp steps down as Ultragenyx CFO; plus Axsome, ElevateBio, FasterCures, Satsuma, WindMIL and more
BioCentury | Aug 23, 2019
Company News
Aug. 22 Company Quick Takes: Innovent, Lilly in biologics deal; plus Sobi, Gilead, Themis-Merck, Iconic-Novartis, GW, BeiGene, Clearside, Inex Innovations
BioCentury | May 16, 2019
Company News
May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more
BioCentury | Feb 1, 2016
Finance
Unfinished business
Why more crossover rounds in January do not herald a return to 2015 levels
BioCentury | Jan 25, 2016
Finance
Platform Twist
Why crossover investors flocked to DNA synthesis company Twist's series D
Items per page:
1 - 10 of 16